T cells are primary effectors to fight cancer


T cells are immune effectors that recognize and kill malignant cells. The therapeutic use of patient’s T cells, also known as adoptive cell therapy, revolutionized cancer treatment and clinical outcome. Autologous adoptive T cell therapy relies on the transfer of T cells that are derived from the patient’s own blood and generally gene-engineered to express a tumor-specific receptor (in this case a TCR), after which T cells are expanded and re-infused back into the patient.

Inherent to a TCR’s function is to screen and eradicate diseased and cancerous cells. T cells gene-engineered with a TCR against the Cancer Germline Antigen NY-ESO1 have already demonstrated clinical benefit in patients with advanced solid tumors, not responding to standard of care.

To fully fully exploit the therapeutic potential of TCR-engineered T cells, we use our platforms to:

1. Limit toxicity attributed to recognition of identical or highly similar targets outside cancers

2. Deliver shared intracellular targets that are cancer-selective to treat large cohorts of patients

3. Counteract the immune-suppressive nature of tumor microenvironments

Why T cells Foto A